A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

Drugs

Volumn 77, Issue 11, 2017, Pages 1155-1186

  Peter, Wendy L St ^a   Wazny, Lori D ^b   Weinhandl, Eric ^a   Cardone, Katie E ^c   Hudson, Joanna Q ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; BIXALOMER; CALCIUM ACETATE; CALCIUM CARBONATE; CHITOSAN; COLESTILAN; FERRIC CITRATE; IRON; LANTHANUM CARBONATE; MAGNESIUM; MAGNESIUM CARBONATE; NICOTINAMIDE; NICOTINIC ACID; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; ROSIGLITAZONE; SEVELAMER; SEVELAMER CARBONATE; SUCROFERRIC OXYHYDROXIDE; TENAPANOR; CALCIUM DERIVATIVE; CHELATING AGENT; FERRIC ION; LANTHANUM;

ANEMIA; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMPOWERMENT; END STAGE RENAL DISEASE; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INTENTION TO TREAT ANALYSIS; MEDICATION COMPLIANCE; META ANALYSIS; MORTALITY RATE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PERITONEAL DIALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PILL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SALIVA; SURVIVAL RATE; SYSTEMATIC REVIEW; THERAPEUTIC EQUIVALENCE; BLOOD; COMPLICATION; ECONOMICS; META ANALYSIS (TOPIC); METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

CALCIUM COMPOUNDS; CHELATING AGENTS; DRUG COSTS; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; LANTHANUM; META-ANALYSIS AS TOPIC; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; SEVELAMER;

EID: 85020171859     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-017-0758-5     Document Type: Review

References (139)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;76(113):S24.
3. United States Renal Data System. 2016 USRDS annual data report: epidemiology of kidney disease in the United States. 2016 ed. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2016.
4. Dominguez JR, Kestenbaum B, Chonchol M, Block G, Laughlin GA, Lewis CE, et al. Relationships between serum and urine phosphorus with all-cause and cardiovascular mortality: the Osteoporotic Fractures in Men (MrOS) Study. Am J Kidney Dis. 2013;61:555–63.
5. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009;20:397–404.
6. Tuttle KR, Short RA. Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function. Clin J Am Soc Nephrol. 2009;4:1968–73.
7. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627–33.
8. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D’Agostino RB Sr, Gaziano JM, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879–85.
9. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–8.
10. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:2251–7.
11. McGovern AP, de LS, van VJ, Liyanage H, Tomson CR, Gallagher H, et al. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One. 2013;8(9):e74996.
12. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–8.
13. Martin M, Valls J, Betriu A, Fernandez E, Valdivielso JM. Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference. Atherosclerosis. 2015;241:264–70.
14. Saab G, Whooley MA, Schiller NB, Ix JH. Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study. Am J Kidney Dis. 2010;56:496–505.
15. Slinin Y, Blackwell T, Ishani A, Cummings SR, Ensrud KE. Serum calcium, phosphorus and cardiovascular events in post-menopausal women. Int J Cardiol. 2011;149:335–40.
16. Onufrak SJ, Bellasi A, Cardarelli F, Vaccarino V, Muntner P, Shaw LJ, et al. Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality. Am J Epidemiol. 2009;169:67–77.
17. Chartsrisak K, Vipattawat K, Assanatham M, Nongnuch A, Ingsathit A, Domrongkitchaiporn S, et al. Mineral metabolism and outcomes in chronic kidney disease stage 2–4 patients. BMC Nephrol. 2013;14:14.
18. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation. 2009;87:1040–4.
19. Fouque D, Roth H, Pelletier S, London GM, Hannedouche T, Jean G, et al. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets? Nephrol Dial Transplant. 2013;28:360–7.
20. Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T, et al. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2014;63:979–87.
21. Moore J, Tomson CR, Tessa SM, Borrows R, Ferro CJ. Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation. Clin Transplant. 2011;25:406–16.
22. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de FA, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26:1948–55.
23. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407–15.
24. Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int. 2013;83:959–66.
25. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 2012;81:1116–22.
26. Cupisti A, Moriconi D, D’Alessandro C, Verde F, Marchini M, Saba A, et al. The extra-phosphate intestinal load from medications: is it a real concern? J Nephrol. 2016;29:857–62.
27. Benini O, D’Alessandro C, Gianfaldoni D, Cupisti A. Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients. J Ren Nutr. 2011;21:303–8.
28. Sherman RA, Ravella S, Kapoian T. A dearth of data: the problem of phosphorus in prescription medications. Kidney Int. 2015;87:1097–9.
29. Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin Dial. 2005;18:401–8.
30. Sherman RA. Hyperphosphatemia in dialysis patients: beyond nonadherence to diet and binders. Am J Kidney Dis. 2016;67:182–6.
31. Courivaud C, Davenport A. Phosphate removal by peritoneal dialysis: the effect of transporter status and peritoneal dialysis prescription. Perit Dial Int. 2016;36:85–93.
32. Friedman EA. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int Suppl. 2005;96:S2–6.
33. US Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed 27 Jan 2017.
34. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO 2016 clinical practice guideline update on diagnosis, evaluation, prevention and treatment of CKD-MBD: public review draft. August 2016. http://www.kdigo.org/clinical_practice_guidelines/CKD-MBD%20Update/KDIGO%20CKD-MBD%20Update_Public%20Review_Final.pdf. Accessed 22 Jan 2017.
35. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76(Supplement 113):S50–99.
36. Altmann P, Barnett ME, Finn WF. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 2007;71:252–9.
37. Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, et al. Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis. 2016;68:691–702. doi:10.1053/j.ajkd.2016.05.015.
38. Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in ckd: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11:232–44.
39. Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32:111–25.
40. Wang C, Liu X, Zhou Y, Li S, Chen Y, Wang Y, et al. New conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials. PLoS One. 2015;10(7):e0133938.
41. Sekercioglu N, Thabane L, Diaz Martinez JP, Nesrallah G, Longo CJ, Busse JW, et al. Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PLoS One. 2016;11(6):e0156891.
42. Li T, Puhan MA, Vedula SS, Singh S, Dickersin K, The Ad Hoc Network Meta-analysis Methods Meeting Working Group. Network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 2011;9:79. http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-9-79. Accessed 5 Jan 2017.
43. Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol. 2013;14:226.
44. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:556–63.
45. Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011;22:1923–30.
46. Centers for Medicare and Medicaid Services. Medicare provider utilization and payment data: part D prescriber data CY 2014. Drug summary table: “Part D Prescriber National Summary table. CY2014. Microsoft Excel (.xlsx)”. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PartD2014.html. Accessed 27 Jan 2017.
47. Department of Health and Human Services OoIG. High-price drugs are increasing federal payments for Medicare Part D catastrophic coverage. OIG Report: OEI-02-16-00270. https://oig.hhs.gov/oei/reports/oei-02-16-00270.pdf. Accessed 6 Jan 2017.
48. Navaneethan SD, Sakhuja A, Arrigain S, Sharp J, Schold JD, Nally JV Jr. Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease. Clin Nephrol. 2014;82:16–25.
49. Winkelmayer WC, Liu J, Kestenbaum B. Comparative effectiveness of calcium-containing phosphate binders in incident US dialysis patients. Clin J Am Soc Nephrol. 2011;6:175–83.
50. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20:388–96.
51. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis. 2010;56:842–51.
52. Cheng J, Pullenayegum E, Marshall JK, Iorio A, Thabane L. Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open. 2016;6(8):e010983.
53. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–7.
54. Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62:771–8.
55. Yusuf AA, Weinhandl ED, St Peter WL. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D. Am J Kidney Dis. 2014;64:95–103.
56. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492–5.
57. Ogata H, Fukagawa M, Hirakata H, Kaneda H, Kagimura T, Akizawa T. Design and baseline characteristics of the LANDMARK study. Clin Exp Nephrol. 2016. doi:10.1007/s10157-016-1310-8.
58. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51:445–54.
59. St Peter WL, Liu J, Weinhandl ED, Fan Q. Linking Centers for Medicare and Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodial Int. 2008;12:480–91.
60. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.
61. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.
62. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de ZD, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.
63. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638–47.
64. Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, et al. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2016. doi:10.1093/ndt/gfw242. [Epub ahead of print].
65. Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30:1037–46.
66. Koiwa F, Terao A. Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. Clin Exp Nephrol. 2016. doi:10.1007/s10157-016-1299-z. [Epub ahead of print].
67. Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomised, open-label, multicentre, 12-week phase III study. Nephrology (Carlton). 2017;22:293–300.
68. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis. 2013;61:759–66.
69. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26:493–503.
70. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26:2578–87.
71. Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, et al. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res. 2015;15:545–50.
72. Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant. 2014;29:1053–60.
73. Iguchi A, Kazama JJ, Yamamoto S, Yoshita K, Watanabe Y, Iino N, et al. Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency. Nephron. 2015;131:161–6.
74. Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Hirakata H. JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis. Nephron Clin Pract. 2014;128:135–40.
75. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis. 2015;65:728–36.
76. Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, et al. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. J Am Soc Nephrol. 201. doi:10.1681/ASN.2016101053. [Epub ahead of print].
77. Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9:543–52.
78. US Food and Drug Administration. Ferric citrate tablets. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000TOC.cfm. Accessed 11 Apr 2017.
79. Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel). 2014;7:990–8.
80. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, et al. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am J Kidney Dis. 2015;66:479–88.
81. Ghimire S, Castelino RL, Lioufas NM, Peterson GM, Zaidi ST. Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLoS One. 2015;10(12):e0144119.
82. Wang S, Anum EA, Ramakrishnan K, Alfieri T, Braunhofer P, Newsome B. Reasons for phosphate binder discontinuation vary by binder type. J Ren Nutr. 2014;24:105–9.
83. Arenas MD, Rebollo P, Malek T, Moledous A, Gil MT, Alvarez-Ude F, et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol. 2010;23:683–92.
84. Yusuf AA, St Peter WL. Medication adherence in hemodialysis patients treated with phosphate binders. Value Health. 2012;15:A153 (abstract PUK6).
85. Arenas MD, Malek T, Alvarez-Ude F, Gil MT, Moledous A, Reig-Ferrer A. Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control. Nefrologia. 2010;30:522–30.
86. Daugirdas JT, Finn WF, Emmett M, Chertow GM. The phosphate binder equivalent dose. Semin Dial. 2011;24:41–9.
87. Coyne DW, Larson DS, Delmez JA. Bone Disease. In: Daugirdas JT, Blake PG, Ing TS, editors. Handbook of dialysis. 5th ed. Philadelphia: Wolters Kluwer Health; 2015. p. 665–92.
88. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989;83:66–73.
89. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12:1640–4.
90. Kuhlmann MK. Management of hyperphosphatemia. Hemodial Int. 2006;10:338–45.
91. Ahlenstiel T, Pape L, Ehrich JH, Kuhlmann MK. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Nephrol Dial Transplant. 2010;25:3241–9.
92. Stuart BC, Dai M, Xu J, Loh FH, Dougherty S. Does good medication adherence really save payers money? Med Care. 2015;53:517–23.
93. Murali K, Mullan J, Roodenrys S, Chen J, Lonergan M. Treatment adherence in clinical trials evaluating cardiovascular or mortality outcomes in dialysis patients: a systematic review. Nephrology. 2015;20(Supp. S3):32 (Abstract 053).
94. Rizk R, Hiligsmann M, Karavetian M, Evers SM. Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: a systematic review. Nephrology (Carlton). 2016;21:178–87.
95. Goto S, Komaba H, Fukagawa M, Nishi S. Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney Int Suppl. 2013;3:457–61.
96. National Institute for Health and Care Excellence (NICE). Appendix F: full health economic report. NICE clinical guideline 157-hyperphosphataemia in chronic kidney disease. 2013. https://www.nice.org.uk/guidance/cg157/evidence/appendix-f-full-health-economic-report-189805647. Accessed 26 Oct 2016.
97. National Institute for Health and Care Excellence (NICE). Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia: clinical guideline [CG157]. https://www.nice.org.uk/guidance/cg157. Accessed 26 Oct 2016.
98. Gutzwiller FS, Pfeil AM, Ademi Z, Blank PR, Braunhofer PG, Szucs TD, et al. Cost effectiveness of sucroferric oxyhydroxide compared with sevelamer carbonate in the treatment of hyperphosphataemia in patients receiving dialysis, from the perspective of the National Health Service in Scotland. Pharmacoeconomics. 2015;33:1311–24.
99. Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis. 2014;7:191–201.
100. Rodby RA, Umanath K, Niecestro R, Bond TC, Sika M, Lewis J, et al. Ferric citrate, an iron-based phosphate binder, reduces health care costs in patients on dialysis based on randomized clinical trial data. Drugs R D. 2015;15:271–9.
101. Mutell R, Rubin JL, Bond TC, Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis. 2013;6:79–87.
102. Vegter S, Tolley K, Keith MS, Postma MJ. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health. 2011;14:852–8.
103. Thompson M, Bartko-Winters S, Bernard L, Fenton A, Hutchison C, Di IB. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. J Med Econ. 2013;16:744–55.
104. Gros B, Galan A, Gonzalez-Parra E, Herrero JA, Echave M, Vegter S, et al. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis. Health Econ Rev. 2015;5:49.
105. Nguyen HV, Bose S, Finkelstein E. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. BMC Nephrol. 2016;17:45.
106. National Institute for Health and Care Excellence (NICE). Hyperphosphataemia in chronic kidney disease: evidence update December 2014. https://www.nice.org.uk/guidance/cg157/evidence/evidence-update-18980175. Accessed 27 Oct 2016.
107. Rizk R. Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go. BMC Nephrol. 2016;17:75.
108. John-Baptiste A, Bell C. Industry sponsored bias in cost effectiveness analyses. BMJ. 2010;341:c5350.
109. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70.
110. Evers SM, Hiligsmann M, Adarkwah CC. Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies. Psychol Health. 2015;30:52–71.
111. Goeree R, Burke N, O’Reilly D, Manca A, Blackhouse G, Tarride JE. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin. 2007;23:671–82.
112. Perry CM, Plosker GL. Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease. Drugs. 2014;74:771–92.
113. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1131–8.
114. Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int. 2009;29:562–7.
115. El Borolossy R, El Wakeel LM, El Hakim I, Sabri N. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr Nephrol. 2016;31(2):289–96.
116. Lenglet A, Liabeuf S, El EN, Brisset S, Mansour J, Lemaire-Hurtel AS, et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2016. doi:10.1093/ndt/gfw042.
117. Lenglet A, Liabeuf S, Bodeau S, Louvet L, Mary A, Boullier A, et al. N-methyl-2-pyridone-5-carboxamide (2PY)-major metabolite of nicotinamide: an update on an old uremic toxin. toxins (Basel). 2016;8. doi:10.3390/toxins8110339.
118. Ginsberg C, Ix JH. Nicotinamide and phosphate homeostasis in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25:285–91.
119. Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Astrand M, Johansson S, Knutsson M, et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017. doi:10.1681/ASN.2016080855. [Epub ahead of print].
120. Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol. 2017. doi:10.1038/ajg.2017.41. [Epub ahead of print].
121. Johansson SA, Knutsson M, Leonsson-Zachrisson M, Rosenbaum DP. Effect of food intake on the pharmacodynamics of tenapanor: a phase 1 study. Clin Pharmacol Drug Dev. 2017. doi:10.1002/cpdd.341. [Epub ahead of print].
122. Locatelli F, Dimkovic N, Spasovski G. Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. Expert Opin Pharmacother. 2014;15:1475–88.
123. Locatelli F, Spasovski G, Dimkovic N, Wanner C. Long-term evaluation of colestilan in chronic kidney disease stage 5 dialysis patients with hyperphosphataemia. Blood Purif. 2016;41:247–53.
124. Ito K, Takeshima A, Shishido K, Wakasa M, Kumata C, Matsuzaka K, et al. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. Ther Apher Dial. 2014;18(Suppl 2):19–23.
125. Gen S, Sasaki T, Saito K, Nobe K, Nodaira Y, Ikeda N. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride. Ther Apher Dial. 2014;18(Suppl 2):8–12.
126. Savica V, Calo LA, Monardo P, Davis PA, Granata A, Santoro D, et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol. 2009;20:639–44.
127. Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, et al. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract. 2013;123:93–101.
128. Akizawa T, Tsuruta Y, Okada Y, Miyauchi Y, Suda A, Kasahara H, et al. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial. BMC Nephrol. 2014;15:98.
129. Oh MS, Uribarri J. What can we learn from the saga of chitosan gums in hyperphosphatemia therapy? Clin J Am Soc Nephrol. 2014;9:967–70.
130. Nakaki J, Yamaguchi S, Torii Y, Inoue A, Minakami S, Kanno T, et al. Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer. Eur J Pharmacol. 2013;714:312–7.
131. Moustafa M, Lehrner L, Al-Saghir F, Smith M, Goyal S, Dillon M, et al. A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis. Int J Nephrol Renovasc Dis. 2014;7:141–52.
132. Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 2010;77:897–903.
133. Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton). 2011;16:743–50.
134. Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract. 2008;108:c278–83.
135. Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. 2011;2:CD006023.
136. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268–77.
137. Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009;24:3168–74.
138. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;54:619–37.
139. Coyne DW, Larson DS, Delmez JA. Bone disease. In: Daugirdas JT, Blake PG, Ing TS, editors. Handbook of dialysis. 5th ed. Philadelphia: Wolters Kluwer Health; 2015. p. 673 (Table 36.3).